D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Drew Weissman(California University of Pennsylvania), David C. Montefiori(Duke University), S. Gobeil(Duke University), Pamela A. Shaw(University of Pennsylvania), Bette Korber(Los Alamos National Laboratory), Laura L. Sutherland(Duke University), Paul Collini(Sheffield Teaching Hospitals NHS Foundation Trust), Charlene McDanal(Duke University), Nicolas Hengartner(Los Alamos National Laboratory), Paulo J.C. Lin(University of British Columbia), Mark G. Lewis(Bioqual), Barton F. Haynes(Duke University), Thushan I. de Silva(Sheffield Teaching Hospitals NHS Foundation Trust), Celia C. LaBranche(Duke University), Katayoun Mansouri(Duke University), Ying K. Tam(Arbutus Biopharma (Canada)), Norbert Pardi(University of Pennsylvania), Mohamad‐Gabriel Alameh(Children's Hospital of Philadelphia), Uğur Şahin(Johannes Gutenberg University Mainz), Rebecca Brown(University of Sheffield), Hailey Hornsby(University of Sheffield), Carsten Boesler(BioNTech (Germany)), Priyamvada Acharya(Duke University), Robert J. Edwards(Duke University), Sampa Santra(Beth Israel Deaconess Medical Center)
Cited by 354
Related Papers
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
mRNA vaccines — a new era in vaccinology
|Nature Reviews Drug Discovery|2018|4.4k
Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS
|Science|1984|3.6k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k